Sangamo Therapeutics, Inc (SGMO) Stock Price & Analysis
Sangamo Therapeutics, Inc (SGMO) fell 15.63% to USD 0.15 as of June 10, 2026 at 07:06 UTC, according to Nexqual real-time market data.
SGMO last closed at USD 0.17; the session ranged USD 0.13–0.19 on volume of 2,597,980 shares. Market capitalization is $60.15M, with a 52-week range of USD 0.1–0.77 (OQB). Source: Nexqual, June 10, 2026 at 07:06 UTC.
Key Statistics (as of June 10, 2026 at 07:06 UTC)
| Price | USD 0.15 |
|---|---|
| Change | ▼ 15.63% (down) |
| Previous Close | USD 0.17 |
| Open | USD 0.17 |
| Day Range | USD 0.13 – 0.19 |
| 52-Week Range | USD 0.1 – 0.77 |
| Volume | 2,597,980 shares |
| Market Cap | $60.15M |
| Exchange | OQB |
Technical Analysis (SGMO)
Nexqual's technical model rates SGMO "SELL" based on 1 bullish and 4 bearish signals across 123 daily candles, as of June 10, 2026 at 07:06 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 42.13 (neutral) |
| vs SMA50 | Below (USD 0.21) |
| MACD | 0 (positive) |
Analyst Ratings (SGMO)
Wall Street analysts rate SGMO "Buy" based on 4 analysts, with a mean price target of USD 2.5 (range USD 1–5), per Nexqual as of June 10, 2026 at 07:06 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 4 |
| Mean Target | USD 2.5 |
| High Target | USD 5 |
| Low Target | USD 1 |
| Buy / Hold / Sell | 2 / 2 / 0 |
Earnings (SGMO)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD -0.05 |
| Revenue Estimate | $10.15M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.08 vs est -0.07 ▼ miss |
| 2025-12-31 | USD -0.07 vs est -0.05 ▼ miss |
| 2025-09-30 | USD -0.11 vs est -0.1 ▼ miss |
| 2025-06-30 | USD -0.08 vs est -0.13 ▲ beat |
Source: Nexqual, June 10, 2026 at 07:06 UTC.
Financials & Fundamentals (SGMO)
| Total Revenue | $34.56M |
|---|---|
| Revenue Growth (YoY) | -77.60% |
| Gross Margin | -227.67% |
| Operating Margin | -2215.39% |
| Profit Margin | +0.00% |
| Current Ratio | 0.7 |
| Total Cash | $27.59M |
| Total Debt | $19.33M |
| Free Cash Flow | $-48.58M |
Source: Nexqual, June 10, 2026 at 07:06 UTC.
Financial Health Score (SGMO)
Nexqual rates Sangamo Therapeutics, Inc's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 07:06 UTC.
| Growth | Critical — Revenue -32% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $28M cash vs $19M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$49M, burning cash |
| Efficiency | Mixed — No data |
Ownership (SGMO)
| Insider Ownership | +1.76% |
|---|---|
| Institutional Ownership | +25.84% |
| Shares Outstanding | 414.29M |
| Float | 370.04M |
| Short % of Float | +10.42% |
Source: Nexqual, June 10, 2026 at 07:06 UTC.
Leadership (SGMO)
Sangamo Therapeutics, Inc is led by Alexander D. Macrae Ch.B, M.B., MRCP (age 62), CEO, President & Director, per Nexqual as of June 10, 2026 at 07:06 UTC.
| CEO, President & Director | Alexander D. Macrae Ch.B, M.B., MRCP (age 62) |
|---|---|
| Interim CFO and Principal Financial & Accounting Officer | Nikunj Jain (age 45) |
Major Backers & Investors (SGMO)
Notable institutional backers of Sangamo Therapeutics, Inc include Armistice Capital, LLC, Two Sigma Investments, LP, Balyasny Asset Management LP, according to Nexqual as of June 10, 2026 at 07:06 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Armistice Capital, LLC | 9.75% |
| Two Sigma Investments, LP | 1.51% |
| Balyasny Asset Management LP | 1.28% |
| Renaissance Technologies | 0.93% |
| Fidelity | 0.78% |
| UBS Group AG | 0.62% |
| Charles Schwab Investment Management, Inc. | 0.57% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 6.63% |
| BlackRock | 1.18% |
| Geode Capital | 1.1% |
Source: Nexqual, June 10, 2026 at 07:06 UTC.
From Sangamo Therapeutics, Inc's Latest SEC 10-K Filing (filed 2026-03-30)
Key Strengths & Strategy (as disclosed to the SEC)
- Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States.
- Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Genentech, Inc.; Astellas Gene Therapies, Inc.; Capsid Delivery License Agreement with Eli Lilly and Company; Alexion Pharmaceuticals, Inc. ALS and Frontotemporal Lobar Degeneration; Takeda Huntington's Disease; and other areas, such as plant agriculture and research reagents, including the production of transgenic animals and cell-line engineering with Corteva AgriScience and Open Monoclonal Technology, Inc.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| EDIT | Editas Medicine, Inc. | USD 2.65 | ▼ 2.21% |
| NTLA | Intellia Therapeutics, Inc. | USD 12.89 | ▼ 4.8% |
| NKTR | Nektar Therapeutics | USD 56.23 | ▼ 1.9% |
| ALNY | Alnylam Pharmaceuticals, Inc. | USD 297.69 | ▼ 1.77% |
| QURE | uniQure N.V. | USD 26.46 | ▲ 0.04% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 07:06 UTC. This page is informational and not investment advice.